Given that ARHGEF10 and RhoA exert similar inhibitory effects on TRPV4 channel activity and also interact functionally with one another (67, 69, 70), an important focus of future research will be to understand how the interplay between these three interactors regulates both TRPV4 and RhoA activity levels, as well as how alterations in these modulatory pathways may contribute to neuromuscular disease. This evidence concerns the gene ARHGEF10 and neuromuscular disease.